SORAHAIC
Regimen
- Experimental
- sorafenib + HAIC FOLFOX (oxaliplatin, 5-FU, leucovorin)
- Control
- sorafenib alone
Population
Hepatocellular carcinoma with portal vein invasion (Chinese multicentre)
Key finding
mOS 13.37 vs 7.13 mo (HR 0.35, P<0.001); ORR 40.8% vs 2.46%. Transforms HAIC from fringe to mainstream locoregional option in China for HCC with PVI.
Source: PMID 31070690